Ju-sheng Lin

发表

Effects of two novel nucleoside analogues on different hepatitis B virus promoters.

Xing-Xing He, Ju-sheng Lin, Ying Chang, 2008, World journal of gastroenterology.

Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems

Xing-Xing He, Ju-sheng Lin, Jingjun Yan, 2014, Tumor Biology.

RASSF2 Induces Activated Ras-Dependent Cell Growth Inhibition and Apoptosis in Human Pancreatic Cancer Cells

Chao Li, Ju-sheng Lin, Ying Chang, 2006 .

Mcl-1 as a potential therapeutic target for human hepatocelluar carcinoma

Ju-sheng Lin, Qiong Chen, Zhao-yu Liu, 2016, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[2010 guideline for the management of hepatocellular carcinoma recommended by the American Association for the Study of Liver Diseases].

Xing-Xing He, Ju-sheng Lin, D. Tian, 2011, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

Advances in research on hepatitis B virus DNA integration

Ju-sheng Lin, Lin-lin Gao, 2008, Virologica Sinica.

Inhibition of the replication of hepatitis B virus in vitro by a novel 2,6-diaminopurine analog, beta-LPA.

Xing-Xing He, Ju-sheng Lin, Ying Chang, 2008, Biochemical and biophysical research communications.

[Clinical study of lamivudine and interferon combinate administration to inhibit hepatitis B virus replication].

Wang-xian Tang, Ju-sheng Lin, Jian-guo Lin, 2004, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

MiR-192 inhibits nucleotide excision repair by targeting ERCC3 and ERCC4 in HepG2.2.15 cells.

Xing-Xing He, Ju-sheng Lin, Ying Chang, 2011, Biochemical and biophysical research communications.

The emerging role of miR‐375 in cancer

Xing-Xing He, Ju-sheng Lin, Junwei Yan, 2014, International journal of cancer.

Bioinformatics analysis identifies miR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor properties.

An-Yuan Guo, Ying Chang, A. Guo, 2014, Oncology reports.

The regulation of microRNA expression by DNA methylation in hepatocellular carcinoma.

A. Guo, Jing Gong, Xing-Xing He, 2015, Molecular bioSystems.

MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1

Xing-Xing He, Ju-sheng Lin, Ying Chang, 2015, Oncotarget.

[Hammerhead ribozyme against human telomerase catalytic subunit (hTERT) induced apoptosis of liver cancer cells].

Ju-sheng Lin, Pei-Yuan Li, Xin Ma, 2004, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

Targeting gene therapy for hepatocarcinoma cells with the E. coli purine nucleoside phosphorylase suicide gene system directed by a chimeric alpha-fetoprotein promoter.

Xuemei Sun, Ju-sheng Lin, Ying Chang, 2008, Cancer letters.

Effect of ribozyme against transforming growth factorβ1 on biological character of activated HSCs

Ju-sheng Lin, You-xin Jin, Xiulan Xue, 2005, IUBMB life.

miR-30a-3p inhibits the proliferation of liver cancer cells by targeting DNMT3a through the PI3K/AKT signaling pathway

Ju-sheng Lin, Yuan Gao, H. Mei, 2019, Oncology letters.

[MiR-122 regulates the expression of PEG10 in hepatoma cell lines].

Ju-sheng Lin, Ying Chang, Pei-Yuan Li, 2010, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

Gold nanoparticles delivered miR-375 for treatment of hepatocellular carcinoma

Ju-sheng Lin, Robert J. Lee, Lei Li, 2016, Oncotarget.

(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity.

R. Ptak, Y. Cheng, Ju-sheng Lin, 1998, Journal of medicinal chemistry.

Downregulation of MiR-93 expression reduces cell proliferation and clonogenicity of HepG2 cells.

Ju-sheng Lin, Ying Chang, Dong Xu, 2012, Hepato-gastroenterology.